D-dimer Can Be Used to Identify Vicious Phenotype in Gastric Cancer Patients With TNMⅠ-Ⅱ Stages: a Single Institution Experience Over 10 Years Study

Abstract BackgroundPart of gastric cancer (GC) patients in early stages still endure early relapse after systematic treatment. This study was designed to identify the value of d-dimer reflecting the bad phenotype in early GC patients. MethodsFrom January 1 st 2009 to January 1 st 2019, 467 primary GC patients with TNM stage I-II after R 0 resection were enrolled, tumor stage was classified by the national comprehensive cancer network guideline 2019. Plasma D-dimer and associated factors were reviewed and analyzed with clinic-pathological characteristics, regularly follow up was proceed when first determined. ResultsThe median follow up is 33 months, and 381/467 GC patient survived after ten years follow up. Although D-dimer was significantly elevated in old age and vascular cancer emboli positive patients. Noteworthy, D-dimer levels displayed an increase in 48/467 GC patients when the cut-off values was 1.5 mg/ml based on the ROC curve in our previous study, log-rank and Cox hazard model analysis showed D-dimer is an independent risk factor for overall survival and disease free survival in this classification. ConclusionPlasma D-dimer represents an easy measurement and lower cost marker for the routine testing to predict highmalignancy phenotype in stage I-II gastric cancer after R0 resection.Clinical registrationChiCTR1900028178